Ionis Pharmaceuticals/$IONS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
- Ticker
- $IONS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,480
- Headquarters
- Carlsbad, United States
- Website
- www.ionis.com
IONS Metrics
BasicAdvanced
$7.4B
-
-$3.47
0.42
-
Price and volume
Market cap
$7.4B
Beta
0.42
52-week high
$86.74
52-week low
$42.08
Average daily volume
3.8M
Financial strength
Current ratio
7.886
Quick ratio
6.69
Long term debt to equity
4.945
Total debt to equity
4.978
Interest coverage (TTM)
-6.06%
Profitability
EBITDA (TTM)
-579.485
Gross margin (TTM)
-6.93%
Net profit margin (TTM)
-64.73%
Operating margin (TTM)
-68.02%
Effective tax rate (TTM)
-0.56%
Revenue per employee (TTM)
$590,000
Management effectiveness
Return on assets (TTM)
-12.42%
Return on equity (TTM)
-105.50%
Valuation
Price to revenue (TTM)
8.196
Price to book
16.68
Price to tangible book (TTM)
16.68
Price to free cash flow (TTM)
-12.621
Free cash flow yield (TTM)
-7.92%
Free cash flow per share (TTM)
-3.479
Growth
Revenue change (TTM)
-7.41%
Earnings per share change (TTM)
100.84%
3-year revenue growth (CAGR)
11.48%
10-year revenue growth (CAGR)
17.38%
3-year earnings per share growth (CAGR)
16.93%
10-year earnings per share growth (CAGR)
6.28%
What the Analysts think about IONS
Analyst ratings (Buy, Hold, Sell) for Ionis Pharmaceuticals stock.
Analyst projections of the future price of Ionis Pharmaceuticals stock.
Bulls say / Bears say
TRYNGOLZA’s approval for severe hypertriglyceridaemia expands its opportunity beyond the rare FCS market, and Ionis reported early launch momentum after the June approval. The company is targeting $100–110 million in 2026 sales, with longer-term growth resting on this broader indication. (Nasdaq)
The FDA approved ZANVASTRO for Alexander disease, making it the first disease-modifying treatment for the condition and Ionis’ first independent neurology launch. This gives the company a new owned product and a commercial foothold in its neurology pipeline. (The Catalyst Brief)
Partner Roche reported that Phase 3 sefaxersen met its primary endpoint in IgA nephropathy, with clinically meaningful improvement in proteinuria and no new safety signal. Ionis may benefit through further milestones and royalties if the partnered drug advances towards approval and sales. (SEC)
Two partnered cardiovascular programmes have suffered late-stage setbacks: eplontersen missed its primary endpoint in ATTR cardiomyopathy, and pelacarsen failed to reduce cardiovascular events despite lowering Lp(a). These results remove or weaken potential sources of future growth and royalties. (SEC, Finviz)
TRYNGOLZA generated only about $5 million in Q2, following a price reduction, while Ionis maintained its $100–110 million sales target for 2026. That target depends on a sharp second-half ramp, so weaker uptake would put guidance at risk. (Nasdaq)
Ionis still expects a non-GAAP operating loss of $425–475 million in 2026, with spending rising to support several product launches. Reaching its 2028 cash-flow breakeven goal therefore depends on commercial growth catching up with those costs. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.
IONS Financial Performance
Revenues and expenses
IONS Earnings Performance
Company profitability
Upcoming events
No upcoming events
IONS News
AllArticlesVideos
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Business Wire16 hours ago
Ionis ranked #1 on Science's Top Employers list
Business Wire2 days ago
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
Business Wire3 days ago
Funds containing IONS
AllUSDEURGBP
Fund name | Fund size | $IONS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.48% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.48% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.14% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.14% |
iShares MSCI World Small Cap£WLDS | $9B | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.